The ENL-USP7 Complex Regulates HIV Latency Through BRD4 Stabilization

This study identifies the ENL-USP7 complex as a critical host factor that enforces HIV-1 latency by stabilizing BRD4 through deubiquitination, demonstrating that disrupting this axis with PROTACs effectively reactivates latent virus in diverse cellular models.

The Gist

The Big Picture: The HIV "Sleeping Beauty" Problem

Imagine HIV as a tiny, mischievous spy that hides inside your body's security guards (immune cells). When you take HIV medication (antiretroviral therapy), the spy goes into a deep sleep called latency. It stops making noise, stops copying itself, and becomes invisible to your immune system and the drugs.

The problem is that this spy never truly dies; it just waits. If you stop taking your medication, the spy wakes up, multiplies, and the infection returns. Scientists have been trying to find a way to "wake up" every single spy so the immune system can catch and destroy them all (a strategy called "Shock and Kill").

This paper discovers a new set of "sleeping pills" that the spy uses to stay asleep, and it finds a way to remove those pills to wake the spy up.

---

The Main Characters

To understand the discovery, let's meet the three key players in this story:

1. ENL (The Security Guard): Think of ENL as a very strict security guard standing at the front door of the spy's hideout. For a long time, scientists thought this guard was there to help the spy get out and cause trouble. This paper reveals the opposite: ENL is actually the one locking the door to keep the spy asleep.
2. USP7 (The Bodyguard): USP7 is a protein that acts like a bodyguard for another character. Its job is to make sure its partner doesn't get destroyed by the cell's cleanup crew.
3. BRD4 (The Heavy Hitter): BRD4 is a powerful protein that, in this specific context, acts as a "brake" on the virus. It keeps the viral engine turned off.

The Discovery: A Secret Alliance

The researchers found that these three characters form a secret team: ENL + USP7 + BRD4.

Here is how they work together to keep HIV asleep:

• ENL acts as the recruiter. It calls USP7 to the scene.
• USP7 arrives and acts as a shield for BRD4. It removes "trash tags" (ubiquitin) that would normally mark BRD4 for destruction.
• Because USP7 protects it, BRD4 stays strong and keeps the HIV virus firmly locked down, preventing it from waking up.

The Analogy:
Imagine HIV is a car parked in a garage.

• BRD4 is the heavy lock on the garage door.
• USP7 is the mechanic who constantly repairs the lock so it never breaks.
• ENL is the foreman who calls the mechanic to the garage to fix the lock.

As long as the foreman (ENL) calls the mechanic (USP7), the lock (BRD4) stays perfect, and the car (HIV) stays trapped inside.

The Breakthrough: Breaking the Chain

The researchers asked: What happens if we break this team apart?

They used special molecular tools (called PROTACs and inhibitors) to target ENL and USP7. Think of these tools as "saboteurs" that either knock out the foreman or fire the mechanic.

1. When they removed ENL: The foreman was gone. The mechanic (USP7) wasn't called to the garage.
2. When they removed USP7: The mechanic was fired. The lock (BRD4) stopped being repaired.
3. The Result: Without the mechanic, the lock (BRD4) fell apart and was destroyed. With the lock gone, the garage door swung open, and the car (HIV) woke up and started moving!

Why This Matters

This is a huge deal for two reasons:

1. It changes the rules: Scientists used to think ENL was a "villain" that helped HIV wake up. This paper proves ENL is actually a "hero" for the virus's sleep, and removing it wakes the virus up.

2. It works in the "Hard-to-Reach" places: HIV hides in two main places:

   • Resting T-cells: The standard immune cells in the blood.
   • Microglia: The immune cells inside the brain.

   The researchers tested their "saboteurs" on cells from real people with HIV. They found that breaking the ENL-USP7 team successfully woke up the virus in both the blood cells and the brain cells. This is crucial because the brain is a "safe house" where HIV often hides from drugs, and finding a way to wake it up there is a major step toward a cure.

The Bottom Line

This paper identifies a specific "lock-and-key" mechanism (ENL recruiting USP7 to protect BRD4) that keeps HIV dormant. By using new drugs to break this link, scientists can force the hidden virus to wake up. Once it's awake, the immune system or other treatments can finally destroy it, potentially leading to a functional cure for HIV.

In short: They found the master switch that keeps HIV asleep, figured out how the virus uses a bodyguard to protect that switch, and found a way to cut the bodyguard's throat, forcing the virus to reveal itself.

Technical Summary

1. Problem Statement

Despite the success of antiretroviral therapy (ART) in suppressing viral replication, HIV-1 persists in long-lived reservoirs (primarily resting CD4⁺ T cells and brain microglia) as transcriptionally silent proviruses. Current "shock and kill" strategies aim to reverse latency by activating viral transcription, but they often fail to eradicate the reservoir.

• The Knowledge Gap: The Super Elongation Complex (SEC), which contains the YEATS domain protein ENL (MLLT1), has traditionally been viewed as a transcriptional activator of HIV. However, emerging evidence suggests SEC components might repress HIV transcription, yet the molecular mechanism behind this paradoxical suppressive role remains unclear.
• The Objective: To identify the host factors and molecular mechanisms that stabilize key transcriptional regulators to enforce HIV latency, specifically investigating the role of ENL and its interactors.

2. Methodology

The study employed a multi-faceted approach combining chemical biology, proteomics, genetics, and ex vivo models:

• Chemical Biology Tools:
  • Inhibitors: Used small molecules SR-0813 and ENLi13 to inhibit the YEATS domain of ENL/AF9.
  • PROTACs (Proteolysis-Targeting Chimeras): Utilized selective degraders MS41 and Cpd-1 (targeting ENL) and CST967 (targeting USP7) to induce protein degradation rather than just inhibition.
• Proteomics:
  • TurboID Proximity Labeling: Generated a doxycycline-inducible ENL-TurboID fusion in Jurkat 2D10 cells to map the ENL interactome. Mass spectrometry identified 2,037 interacting proteins.
• Genetic Manipulation:
  • CRISPR/Cas9: Used ribonucleoprotein (RNP) electroporation to knock out (KO) ENL, USP7, and BRD4 in latency models.
  • Overexpression: Transfected wild-type (WT) and catalytically inactive (C223S) USP7 mutants into 293T cells to test deubiquitination activity.
• Cellular Models:
  • In Vitro: Jurkat-derived latency models (2D10, J-Lat A1, J-Lat 10.6).
  • Ex Vivo: Resting CD4⁺ T cells isolated from ART-suppressed People With HIV (PWH).
  • Brain Reservoir: Primary brain microglia isolated from the "Last Gift" cohort (PWH donors).
• Assays:
  • Latency Reversal: Quantified via GFP flow cytometry, qPCR, and digital droplet PCR (ddPCR) for HIV RNA.
  • Protein Stability: Western blotting to assess protein levels of ENL, USP7, BRD4, and P-TEFb components (Cyclin T1, CDK9).
  • Mechanistic Validation: Chromatin Immunoprecipitation (ChIP) to assess USP7 recruitment to the HIV promoter; Co-immunoprecipitation (Co-IP) to verify complex formation.
  • Single-Nuclei RNA-seq (snRNA-seq): Profiled CNS transcriptomes from uninfected, viremic, and ART-suppressed individuals to analyze expression of latency regulators in microglia.

3. Key Contributions & Findings

A. ENL Functions as a Transcriptional Suppressor of HIV

Contrary to the prevailing model that ENL activates HIV transcription via the SEC, the authors demonstrated that inhibiting or degrading ENL reactivates latent HIV.

• Treatment with ENL inhibitors (SR-0813, ENLi13) or PROTACs (MS41, Cpd-1) significantly increased HIV GFP expression and transcription in 2D10 and J-Lat cells.
• Inducible overexpression of ENL in 2D10 cells decreased HIV transcription, confirming its suppressive role.

B. Identification of the ENL–USP7–BRD4 Axis

Proximity proteomics revealed that ENL interacts with the deubiquitinase USP7 and the bromodomain protein BRD4.

• USP7 Stabilizes BRD4: Degradation of USP7 (via PROTAC CST967) or genetic KO of USP7 led to a rapid loss of BRD4 protein levels, while BRD4 mRNA remained unchanged. This indicates USP7 stabilizes BRD4 post-translationally.
• ENL Recruits USP7: Degradation of ENL (via Cpd-1/MS41) also caused a loss of BRD4 protein, suggesting ENL recruits USP7 to the complex to maintain BRD4 stability.
• Mechanism: USP7 acts as a deubiquitinase that removes ubiquitin chains from BRD4, preventing its proteasomal degradation. This was confirmed by showing that WT-USP7, but not the catalytically inactive C223S mutant, could stabilize BRD4.

C. Reactivation of Latent HIV in Primary Cells

Disruption of this axis effectively reversed latency in clinically relevant models:

• Resting CD4⁺ T Cells: Treatment with ENL or USP7 PROTACs reactivated HIV in cells from 6–7 out of 8 ART-suppressed donors (measured by ddPCR).
• Brain Microglia: Single-nuclei RNA-seq showed persistent high expression of ENL, USP7, and BRD4 in microglia from ART-suppressed individuals. Treating primary microglia from PWH with these PROTACs induced robust HIV reactivation (up to 8-fold).

D. Specificity and Safety

• The degradation of USP7 or ENL specifically reduced BRD4 levels without affecting other critical SEC components like Cyclin T1 or CDK9.
• The treatments showed no detectable cellular toxicity in the tested models.

4. Significance

• Paradigm Shift: This study overturns the long-held belief that ENL is a primary activator of HIV transcription. Instead, it identifies ENL as a critical suppressor that enforces latency by organizing a complex with USP7 to stabilize the latency-promoting factor BRD4.
• Novel Therapeutic Target: The ENL–USP7–BRD4 axis is identified as a critical vulnerability in the HIV reservoir. Targeting USP7 or ENL with small molecules or PROTACs offers a new strategy for "shock and kill" approaches.
• Brain Reservoir Implications: The findings extend beyond T cells, demonstrating that this mechanism is active in brain microglia, a major sanctuary for HIV persistence. This suggests that therapies targeting this axis could be crucial for clearing the CNS reservoir.
• Mechanistic Insight: The study elucidates a previously unknown post-translational regulation of BRD4 stability mediated by the SEC component ENL and the deubiquitinase USP7, providing a molecular explanation for how the SEC can repress viral transcription.

Conclusion

The paper establishes that the ENL–USP7 complex maintains HIV-1 latency by stabilizing BRD4 through deubiquitination. Disrupting this complex via selective degradation of ENL or USP7 destabilizes BRD4, releases the transcriptional block, and reactivates latent HIV in both T cells and brain microglia. This reveals a promising new therapeutic avenue for HIV cure strategies.